Introduction {#Sec1}
============

Novel vaccine development requires a balance between eliciting a potent immune response while limiting the unintentional induction of hypersensitivity and off-target effects. Virus-like particles (VLPs) are a form of subunit vaccine consisting of self-assembling shells derived from virus capsid proteins. Due to the absence of viral genomic material, VLPs are rendered non-replicative and non-infectious, enhancing their safety profile. In comparison to other subunit vaccines, the resemblance of VLPs to their corresponding native virus provides enhanced immunogenicity and specificity. VLP capsid proteins retain their natural structural conformation, harbouring undamaged antigenic motifs in a more immunologically relevant state than an inactivated virus vaccine. VLPs can also resemble a live attenuated virus without replicative or infectious capacity due to structural similarity and utilisation of similar processing pathways. In general, VLPs are considered significantly safer than many other virally derived vaccines by avoiding potential hazards such as attenuated virus reversion or incomplete inactivation.

The first VLP identified and studied was isolated from patients infected with Hepatitis B virus (HBV) in 1968 (Bayer et al. [@CR4]). Due to the ability of some viral capsid proteins to spontaneously form stable particles, many viruses produce VLPs as a natural by-product of their infection cycle. Engerix (GlaxoSmithKline) was the first human VLP-based vaccine, licensed in 1989 for vaccination against HBV. Since then a number of VLP vaccines have been approved for clinical use, including Epaxal (Crucell) for Hepatitis A virus (HAV), Recombivax (Merck), Hepavax (Crucell), and many others for HBV, Gardasil (Merck), and Cervarix (GlaxoSmithKline) for human papillomavirus (HPV), and Inflexal V (Crucell) for Influenza. Bolstered by the success of these vaccines many new VLPs are being developed, with a selection of examples summarised in Table [9.1](#Tab1){ref-type="table"}. In addition, VLPs have also been produced from various non-human mammalian viruses, primarily for vaccination of livestock. Examples include porcine circovirus (Kim et al. [@CR39]), bovine rotavirus (Rodriguez-Limas et al. [@CR73]), chicken anaemia virus (Noteborn et al. [@CR62]; Koch et al. [@CR42]), SARS coronavirus (Liu et al. [@CR49]), Nipah virus (Walpita et al. [@CR89]), and swine vesicular stomatitis virus (Ko et al. [@CR41]).Table 9.1Examples of VLPs licensed or in clinical trialsVaccine targetCompany/InstitutionAdministration (adjuvant)Expression systemVLP platformAntigenReferences![](312094_1_En_9_Figa_HTML.gif){#d29e443}Respiratory syncytial virusNovavaxIM (aluminum phosphate)Insect (Sf-9 cells)RSVRSV-F proteinGlenn et al. ([@CR28])Norwalk virusLigoCyte PharmaceuticalsIN (±MPL, chitosan, mannitol, sucrose)Insect (Sf-9 cells)NVNV capsid proteinEl-Kamary et al. ([@CR21])Hepatitus B (Engerix-B)GSKIM (aluminum hydroxide)Yeast (*S. cerevisiae*)HBVHBV surface antigenKeating and Noble ([@CR37])Human papilloma virus (Gardasil)MerckIM (aluminum hydroxyphosphate sulphate)Yeast (*S. cerevisiae*)HPVHPV6/11/16/18L1Romanowski ([@CR74])Human papilloma virus (Cervarix)GSKIM (aluminum hydroxide & MPL)Insect (Hi Five cells)HPVHPV16/18 LIRomanowski ([@CR74])Alzheimer's disease (CAD106)Cytos Biotechnology/NovartisSC, IM (unspecified)Bacteria (*E. coli*)Qβ (carrier)Ab 1-6Lemere and Masliah ([@CR46])![](312094_1_En_9_Figb_HTML.gif){#d29e608}Human parvovirus B19 (VAI-VP705)NHI/Meridian Life ScienceIM (MF59)Insect (Sf-9 cells)B19B19 VP1, VP2Bernstein et al. ([@CR6])Human immunodeficiency virusBritish Biotech Pharmaceuticals/NAIDSC/IM, IM (aluminum hydroxide)Yeast (*S. cerevisiae*)Ty p1 (carrier)HIV-1 Gag p17/p24Peters et al. ([@CR68])Oral or rectal (none)RabiesThomas Jefferson UniversityOral (none)Plant (Tg spinach)Alfalfa mosaic virus (carrier)Rabies GP/NPYusibov et al. ([@CR99])![](312094_1_En_9_Figc_HTML.gif){#d29e696}InfluenzaNovavaxIM (none)Insect (Sf-9 cells)Influenza virusA/California/04/09 (H1N1) HA, NALopez-Macias et al. ([@CR51])InfluenzaMedicagoIM (none)Plant (transient *N. benthamiana*)Influenza virusA/California/04/09 (H1N1) HA, NA[@CR59]Breast CancerPevion BiotechIM (none)Cell-freeInfluenza virosome (carrier)Her2/neuWiedermann et al. ([@CR91])Hepatitus A (Eqaxal)CrucellIM (none)Cell-freeInfluenza virosome (carrier)Inactivated Hepatitus A vaccineBovier ([@CR9])Adapted from Kushnir et al. ([@CR43]). *Abbreviations*: *GP* glycoprotein, *HA* haemagglutinin, *HBV*, hepatitis B virus, *HPV* human papillomavirus, *IM* intramuscular, *IN* intra-nasal, *NA* neuraminidase, *NP* nucleocapsid protein, *NV* Norwalk virus, *RSV* respiratory syncytial virus, *SC* sub-cutaneous

VLP Structural Conformation {#Sec2}
===========================

Spontaneous polymerisation of a range of viral capsid proteins can yield VLPs with authentic geometric symmetry, usually icosahedral, spherical or rod-like in shape, depending on the source virus. VLPs can be generally categorised into groups based on their structural complexity, including single-protein non-enveloped (e.g. VLPs derived from caliciviruses (Jiang et al. [@CR34]), papillomaviruses (Kirnbauer et al. [@CR40]), and parvoviruses (Lopez de Turiso et al. [@CR50])), multi-protein non-enveloped (e.g. VLPs derived from infectious bursal disease virus (Kibenge et al. [@CR38]), poliovirus (Brautigam et al. [@CR10]), and reoviruses (French et al. [@CR27]; French and Roy [@CR26])) and enveloped VLPs (e.g. VLPs derived from Hantaan virus (Betenbaugh et al. [@CR7]), hepatitis C virus (Baumert et al. [@CR3]), influenza A (Latham and Galarza [@CR45]), and retroviruses (Yamshchikov et al. [@CR96])) as illustrated in Fig. [9.1](#Fig1){ref-type="fig"}. While single-protein VLPs have a relatively simple structure, multi-protein VLPs can contain unique structural features such as several distinct capsid layers. For example, expression of various combinations of the VP2, VP4, VP6, and VP7 capsid proteins of rotavirus can produce stable VLPs with double or even triple capsid layers (Crawford et al. [@CR17]; Sabara et al. [@CR76]).Fig. 9.1VLP Structure. VLPs can be categorised based on characteristic structural features such as capsid protein composition, encapsulation inside a lipid bilayer envelope, and incorporation of antigens by recombinant insertion or chemical conjugation. Additional combinations other than those illustrated also exist, such as multi-protein chimeric VLPs and enveloped mosaic or chimeric VLPs

Multi-protein VLPs can also be produced from variant copies of the same protein derived from different viral strains. These mosaic VLPs efficiently confer protection against several strains of the same virus (Buonamassa et al. [@CR12]). An alternative means of increasing VLP versatility is through the incorporation of antigens from heterologous sources. Chimeric VLPs contain antigenic material from a target source supported by a stable VLP framework. These antigens can be inserted as peptides into the VLP capsid protein or substructural secondary VLP proteins, or covalently coupled to the surface of VLP. Chimeric VLPs have an extensive range of potential applications, and will be discussed later in this chapter. Enveloped VLPs consist of either a single-protein or multi-protein VLPs encapsulated in a lipid bilayer captured from the cell membrane. Co-expression of haemagglutinin (HA), neuraminidase (NA), matrix protein M1, and ion channel protein M2 from influenza virus produces enveloped VLPs with the same size and morphology as native influenza virions, including the characteristic surface spikes HA and NA (Latham and Galarza [@CR45]). The lipid bilayer of enveloped VLPs can also support the incorporation of transmembrane anchored proteins from multiple viral strains (enveloped mosaic VLPs) or even heterologous pathogens (enveloped chimeric VLPs) (Buonaguro et al. [@CR11]; Halsey et al. [@CR31]; Visciano et al. [@CR88]). VLP structural complexity appears to have few limitations, with intriguing novel constructs still frequently theorised and investigated.

Production of VLPs {#Sec3}
==================

VLPs are a natural by-product produced during the infection cycle of certain viruses (Bayer et al. [@CR4]). The same characteristics that benefit efficient virus reproduction, such as spontaneously polymerising capsid proteins, also promote the formation of VLPs; however, the isolation of VLPs produced from virally infected cells is not an efficient means of purification. An expansive range of protein expression systems have been developed for a variety of applications, and can be effectively commandeered for the production and purification of high quality VLPs. Recombinant expression of viral capsid proteins through tailored expression systems can also enable the production of VLPs from viruses not routinely cultured in laboratories. Common VLP expression systems include bacteria, yeast, insect cell lines, mammalian cell lines, plants, and cell-free cultures. Each expression system has its benefits and pitfalls as outlined in Table [9.2](#Tab2){ref-type="table"} (Rebeaud and Bachmann [@CR72]). While most VLPs can be produced in multiple expression systems, the quaternary structural conformation of the capsid proteins produced can vary due to differences in post-translational modifications such as phosphorylation and glycosylation. This can have significant effects on the immunogenicity of VLPs, as these modifications are often essential for eliciting the desired immune response.Table 9.2VLP expression systemsAdvantagesLimitations**Bacteria** (e.g. *Escherichia coli*) ![](312094_1_En_9_Figd_HTML.gif){#d29e968}• Rapid cell growth• No post-translational modification• Highest yield• Limited applications for mammalian VLPs• Low production cost• May form inclusion bodies• Scalable• Requires removal of endotoxins**Yeast** (e.g. *Saccharomyces cerevisiae*) ![](312094_1_En_9_Fige_HTML.gif){#d29e1008}• Rapid cell growth• Limited post-translational modification• High yield• May form inclusion bodies• Low production cost• Scalable• Already has some regulatory approval**Insect cells/Baculovirus** (e.g. *Spodoptera frugiperda*) ![](312094_1_En_9_Figf_HTML.gif){#d29e1049}• Average cell growth• Requires removal of baculovirus proteins• High yield• May form inclusion bodies• Scalable• Complex post-translational modification• Formation of multi-protein VLP**Plant cells** (e.g. *Nicotiana* sp.) ![](312094_1_En_9_Figg_HTML.gif){#d29e1091}• Rapid production• Limited post-translational modification• Low production cost• Relatively new system• Scalable**Mammalian cells** (e.g. Chinese hamster ovary cells) ![](312094_1_En_9_Figh_HTML.gif){#d29e1119}• Scalable• Slow growth• Complex post-translational modification• Low yield• Formation of multi-protein• Demanding culture conditions• VLP• High production cost• Potential infectious contamination**Cell free** ![](312094_1_En_9_Figi_HTML.gif){#d29e1162}• Almost exclusive production of target protein• Very high production cost• Limited cellular contaminants• Limited scalability• Enables production of VLPs containing non-natural amino acids or toxic protein intermediates• Relatively new system, not well characterisedAdapted from Rebeaud and Bachmann ([@CR72])

*Escherichia coli* (*E. coli*) has long been a primary laboratory workhorse bacterium, facilitating the expression and purification of recombinant proteins through plasmid transformation or bacteriophage vector delivery. Expression in *E. coli* is often preferred when producing small proteins with limited post-translational modifications; however, larger proteins with post-translational modifications require a more complex expression system (e.g. Chinese hamster ovary (CHO) mammalian cell line). The presence of endotoxins during downstream purification also presents a significant challenge for vaccine development from a bacterial expression system. Each VLP is unique, with optimal expression identified through trial and error by comparing the translated products of multiple expression systems. For example, Rabbit Haemorrhagic Disease Virus (RHDV) VLPs can be optimally produced by expressing the RHDV VP60 capsid protein in *Spodoptera frugiperda* (SF) cells using a recombinant baculovirus vector (Young et al. [@CR97], [@CR98]; Peacey et al. [@CR66]). Icosahedral T = 3 VLPs with a diameter of around 40 nm spontaneously form when VP60 is expressed in SF21 cells. Each VLP contains 180 copies of the VP60 capsid protein, representing a relatively simple single-protein non-enveloped VLP. These VLPs structurally resemble native RHDV virions, as illustrated in Fig. [9.2](#Fig2){ref-type="fig"} (Katpally et al. [@CR36]; Wang et al. [@CR90]).Fig. 9.2Comparison of RHDV and RHDV VLP structure. RHDV VLPs expressed in insect cells visibly share structural characteristics with the native virus as viewed by transmission electron microscopy (**a**, **b**) and 3D modelling from cryo-electron microscopy and crystallography (**c**, **d**). (**a**, **c**) Adapted from Wang et al. ([@CR90]). (**d**) Generously supplied by Thomas J. Smith (Katpally et al. [@CR36])

Production of VLPs in transgenic plants (e.g. tobacco, potato, tomato) is a relatively new concept with interesting applications. Expression of recombinant proteins in plants is achieved through transgene insertion into the nuclear or plastid genome, or using plant viral vectors. While plant cells do not have a mammalian-like post-translational modification system, plant-specific glycosylation can have an immunostimulatory effect. Some examples of VLPs produced in a transgenic plant system include Norwalk virus (Tacket [@CR83]; Tacket et al. [@CR84]), HIV-1 (Scotti et al. [@CR79]), and influenza virus VLPs (Medicago). Another recently developed expression platform is the cell-free system. This usually consists of extracts from *E. coli* or yeast cells, and was developed primarily to enable the production of viral capsid proteins which have toxic intermediate protein forms. Development of VLPs containing unnatural amino acids (UAAs) has also been achieved using the cell-free system. The non-replenishing nature of a cell-free system renders this method highly demanding with some scalability limitations. The influenza vaccine Inflexal V (Herzog et al. [@CR32]), and the hepatitis A vaccine Epaxal (Bovier [@CR9]) (Crucell) are two commercialised VLP vaccines that consist of virosomes produced in a cell-free expression system.

Following production, VLPs must be isolated from the expression system and purified to sufficient quality for downstream applications. VLPs are usually isolated through a combination of cell lysis, removal of cellular debris, VLP concentration, and selective purification. Some mammalian and insect cell lines secrete VLPs into the supernatant, negating the necessity for cell lysis (Vicente et al. [@CR87]). Resilient cells (e.g. bacteria, plant cells) may require more robust mechanical manipulation such as ultrasonication, compression, abrasion, repeated freeze/thawing, or enzymatic degradation for VLP release (Cull and McHenry [@CR19]; Salazar and Asenjo [@CR77]). VLPs can be purified by differential centrifugation; however, this can pose limitations on scalability. GMP production of vaccine-grade purified VLPs for commercial applications often involves industrial-scale protein purification methods such as size-exclusion, ion exchange, or affinity chromatography columns (Vicente et al. [@CR87]). Optimal solvent conditions must also be identified to maintain VLP stability. Solution pH is critical, as some VLPs irreversibly denature and disassemble beyond a specific pH range. For example, RHDV VLPs deteriorate in an alkaline environment, with complete VLP disruption above pH 9 (Fig. [9.3](#Fig3){ref-type="fig"}). VLP solubility is another important consideration as some VLPs may aggregate at higher concentrations, forming an insoluble precipitate.Fig. 9.3RHDV VLP stability at an alkaline pH. RHDV VLPs are visibly perturbed under transmission electron microscopy in an elevated solvent pH, resulting in irreversible particle disassembly

VLPs as an Antigen Scaffold {#Sec4}
===========================

VLPs are an incredibly versatile vaccination tool. In addition to harbouring multiple copies of immunologically recognisable antigens from their source virus, VLPs can also be used as a nanoparticulate delivery vector for heterogenous antigenic molecules. Each VLP can be considered a polymerised protein subunit vaccine, supporting modifications such as recombinant peptide insertion and chemical conjugation of peptides, proteins, lysate, carbohydrates, and lipoproteins to form chimeric VLPs. Some VLPs can support insertion of short peptide sequences at specific sites in their structural capsid proteins without impairing VLP formation. For example, RHDV VP60 is known to retain its ability to spontaneously form VLPs despite recombinant insertion of peptides at the N-terminus, C-terminus, or at amino acid residue 306 (Crisci et al. [@CR18]); however, these sites have restrictions on inserted peptide length and residue sequence. The N-terminus of RHDV VP60 can support an insertion of \<33 amino acids (Peacey et al. [@CR66]), while other viral proteins such as polyomavirus VP1 can support insertions ranging from 9 to 120 amino acids (Eriksson et al. [@CR22]; Lasickiene et al. [@CR44]; Mazeike et al. [@CR57]; Middelberg et al. [@CR60]). Inclusion of secondary capsid proteins, such as polyomavirus VP2, with a limited contribution to VLP stability, can support large insertions including truncated proteins (Tegerstedt et al. [@CR85]). HBV core antigen (HBcAg) has been one of the most popular VLP forming viral capsid proteins for recombinant insertion of immunogenic epitopes. Notable recombinant HBc vaccines include Malariavax, which targets *Plasmodium falciparum* (*P. falciparum*); the protozoan responsible for malaria (Gregson et al. [@CR29]), and a pan-influenza A vaccine against the influenza matrix protein 2 (M2e) ectodomain universally conserved between strains (Fiers et al. [@CR25]). The phase I clinical trial of the recombinant influenza A M2e vaccine ACAM-FLU-A reported a 90 % seroconversion rate amongst participants after two vaccinations, with no severe adverse side-effects observed (Fiers et al. [@CR25]).

Recombinant non-mammalian VLPs can also be used to deliver immunogenic peptides derived from mammalian pathogens. Various plant viruses have demonstrated promise as recombinant antigen scaffolds, including alfalfa mosaic virus (AlMV) VLP containing epitopes from HIV-1 or rabies virus (Yusibov et al. [@CR99]), cowpea mosaic virus (CPMV) VLP containing epitopes from *Bacillus anthracis* (Phelps et al. [@CR69]) or HPV16 (Matic et al. [@CR54]) and tobacco mosaic virus (TMV) VLP containing epitopes for *P. falciparum* (Turpen et al. [@CR86]). The potential applications of chimeric VLPs extend far beyond the incorporation of epitopes from mammalian pathogens. VLPs containing auto-antigens naturally present in humans have been harnessed for a variety of novel roles, such as targeting angiotensin II to combat hypertension (Ambuhl et al. [@CR1]; Maurer and Bachmann [@CR55]), targeting Aβ protein to treat Alzheimer's disease (Zamora et al. [@CR100]; Wiessner et al. [@CR92]; Chackerian et al. [@CR13]), or interrupting cytokine signalling pathways (Spohn et al. [@CR82]; Link and Bachmann [@CR48]). VLPs that stimulate an immune response against nicotine have even been investigated for their potential to break smoking addiction (Maurer et al. [@CR56]; Cornuz et al. [@CR16]). The therapeutic application of VLPs can also be used to develop novel vaccines for cancer. For example, recombinant insertion of a truncated form of Her2 protein into polyomavirus VP1/VP2 VLP confers protection against Her2 positive mammary carcinoma (Tegerstedt et al. [@CR85]).

The selected site of recombinant insertion in chimeric VLP provides an inherent limitation on vaccine applications. Recognition of native unprocessed antigen is an essential component of B cell activation in the humoral immune system leading to antibody production. Internal site insertion prevents such interactions, and restricts these sites to insertion of antigenic epitopes that utilise intracellular processing pathways. External site insertion is required for effective B cell activation and depending on the selected VLP this method of chimeric VLP design can have significantly increased complexity. While internal site insertions are typically cloned onto an internal terminus of the VLP capsid protein, external site insertion requires in-depth understanding of the capsid protein quaternary structure and the interactions between each protein subunit to identify the optimal site for insertion. For example, the RHDV VP60 capsid protein is arranged with its N-terminus facing internally and C-terminus facing externally; however, the quaternary structural conformation has the C-terminus folded backwards into the central protein bulk. Amino acid 306 of RHDV VP60 capsid protein was instead identified as a potential external insertion site for exposure of immunogenic peptides tailored for B cell recognition (Crisci et al. [@CR18]).

An alternative means of avoiding the limitations imposed by recombinant peptide insertion is to utilise VLPs as a particulate scaffold for chemical conjugation of antigenic molecules such as peptides, proteins, lysate, carbohydrates, and lipoproteins. Advancement in coupling chemistry continues to expand the list of viable conjugation candidates, primarily limited by their effects on the resulting particles size, solubility, and processing. Conjugation uses a chemical linker as a bridge, commonly conjugating proteins by acylation of amino groups, alkylation of sulfhydryl groups, or the activation of carboxylic acid residues. Some of the most commonly used protein coupling chemistries are illustrated in Fig. [9.4](#Fig4){ref-type="fig"} (Smith et al. [@CR81]). Azide-alkyne click chemistry (Patel and Swartz [@CR65]) and biotin--streptavidin complexes (Chackerian et al. [@CR14]) are also used in VLP conjugation. Heterobifunctional crosslinkers have two reactive groups enabling efficient protein crosslinking; however, this has the unfortunate side-reaction of non-specific conjugation, which can result in protein aggregation in a complex solution such as tumour lysate. Bioorthogonal crosslinkers are a specific alternative that enables selective conjugation, limiting side-reactions by targeting chemical motifs absent in biological systems (e.g. phosphines).Fig. 9.4Chemical conjugation onto the surface of VLPs. Various molecules can be coupled onto the surface of VLPs through chemical conjugation, targeting primary amines (e.g. lysine, N-termini), thiols (e.g. cysteine), carboxylic acids (e.g. glutamic acid, aspartic acid), and phenols (e.g. tyrosine). Unnatural amino acids (UAAs) incorporated into the structure of VLPs can also be used as potential chemical conjugation targets by introducing reactive azide or alkyne groups. Adapted from Smith et al ([@CR81])

Chemical conjugation of immunogenic peptides is a relatively simple alternative to recombinant insertion, using commercial protein crosslinkers such as Sulfo-SMCC (Thermo Fisher Scientific Inc., Rockford, IL, USA). Sulfo-SMCC is a heterobifunctional crosslinker which permits a stepwise conjugation process targeting the amino groups on the VLP surface (NHS-ester) and the sulfhydryl group (maleimide group) from a cysteine residue introduced at the N-terminus of a target epitope (Peacey et al. [@CR67]). Direct comparison between recombinant insertion and chemical conjugation of an H2k^b^-restricted peptide from lymphocytic choreomeningitis virus (LCMV) gp33 in chimeric RHDV VLP indicated that the recombinant form induced a superior in vivo cytotoxic response (Li et al. [@CR47]). Remarkably both the coupled and recombinant forms induced 20 % and 50 % tumour-free survival, respectively, following a single vaccination without adjuvant in mice grafted with Lewis' lung carcinoma tumours expressing gp33. The addition of a 4 week vaccination boost with VLP and adjuvant increased tumour-free survival to 70 % in mice vaccinated with the recombinant gp33 RHDV VLP (Li et al. [@CR47]). Conjugation of large proteins or cell lysate onto the surface of VLPs enables the induction of an immune response without identification of specific immunogenic peptides. Tumour lysates derived from the MART-1 expressing melanoma cell line Mel888 conjugated onto RHDV VLP provides more efficient lysate delivery to dendritic cell antigen processing compartments and enhances MART-1-specific CD8+ T cell stimulation compared to lysate alone (Win et al. [@CR94]). The use of tumour lysate in VLP vaccines has potential applications for personalised anti-cancer immunotherapy.

Intraparticulate Encapsulation {#Sec5}
==============================

Although VLPs are devoid of genomic material from their source virus, they are not necessarily always empty. Many viral structural proteins have an inherent ability to bind specific nucleic acids, facilitating packaging of the viral genome during the infection cycle. This property is retained in some VLPs and can be appropriated for encapsulation of negatively charged molecules such as oligonucleotides and chemical polymers. The primary limitations on intraparticulate encapsulation are the VLPs internal cavity volume and the availability of positively charged amino acids (Zeltins [@CR101]). VLPs with the ability to encapsulate exogenous DNA have been explored as a possible means of gene delivery. VLPs produced from the VP1 capsid protein of the human polyomavirus John Cunningham (JC) virus are a promising candidate, with the ability to harbour DNA plasmids up to 14 kbp in length (Fang et al. [@CR23]). Delivery of pEGFP-C1 plasmid into human epithelial kidney 293 (HEK293) cells and subsequent EGFP production was achieved by loading the plasmid into JC virus VLPs through osmotic shock, which disrupts the VLP structure and increases permeability (Ou et al. [@CR63]). More recently in vivo plasmid loading during expression of VP1 in *E. coli* was found to result in superior plasmid loading over osmotic shock or VLP reassembly, validated with JC virus VLPs encapsulating pEGFP-N3 plasmid (Chen et al. [@CR15]). This loading method was subsequently used with pUMVC1-tk plasmid containing the herpes simplex virus thymidine kinase (tk) suicide gene. JC virus VLPs containing pUMVC1-tk were found to selectively target human colon carcinoma (COLO-320 HSR) cells grafted in nude mice, significantly reducing tumour volume following administration of ganciclovir (Chen et al. [@CR15]).

Chimeric VLPs have also been used to encapsulate DNA plasmids, enabling successful gene delivery upon cellular uptake. Recombinant insertion of the DNA binding site from HPV type 16 (HPV-16) L1 (VP60Δ-L1BS) or L2 (VP60Δ-L2BS) capsid protein onto the N-terminus of RHDV VP60 produces chimeric VLPs with the capacity to encapsulate pCMV-β in vitro through VLP reassembly. β-Galactosidase expression was identified in a range of cell lines (Cos-7, R17, HuH-7, and CaCo~2~) treated with VP60Δ-L1BS containing pCMV-β plasmid (El Mehdaoui et al. [@CR20]). It is possible that any VLP that supports internal site insertion may be capable of DNA plasmid encapsulation and delivery by incorporation of an appropriate DNA binding site. VLPs have even been used to induce the expression of their own structural capsid protein, enhancing immunogenicity by mimicking viral replication in vivo (Pichlmair et al. [@CR70]). A variety of molecules other than nucleic acids have also been successfully encapsulated into VLPs, including enzymes into Qβ VLPs (Fiedler et al. [@CR24]), polymerase into rotavirus VLPs (Boudreaux et al. [@CR8]), and fluorophores into cucumber mosaic virus VLPs (Lu et al. [@CR52]). Recombinant insertion of a heterodimeric coiled-coil amino acid motif at the N-terminus of a capsid protein from cowpea chlorotic mottle virus (CCMV) produced CCMV VLPs capable of encapsulating up to 15 EGFP proteins (Minten et al. [@CR61]). Encapsulating exogenous proteins inside VLPs is an interesting concept with multiple potential therapeutic applications.

VLP Vaccine Immunogenicity {#Sec6}
==========================

The immune response to VLP vaccines is primarily determined by particle size, capsid structure, and innate immunity activation. Particles larger than 200 nm require transportation to the lymph nodes by peripheral antigen presenting cells (APCs) at the vaccination site (e.g. macrophages, dendritic cells) (Manolova et al. [@CR53]). VLPs are usually below 200 nm, facilitating free circulation and drainage directly to lymph nodes in addition to peripheral APC transportation. Once in the lymph node, free VLPs are internalised by resident APCs. The repetitive structure of VLPs promotes efficient uptake by APCs through mechanisms such as phagocytosis and macropinocytosis (Win et al. [@CR93]; Xiang et al. [@CR95]; Scheerlinck and Greenwood [@CR78]). Due to VLPs consisting of native viral capsid proteins, they often contain receptor binding motifs that also enable receptor-mediated endocytosis. An example of this is the binding of haemagglutinin in influenza VLPs to the sialylose receptor on the cell surface (Pan et al. [@CR64]).

The processing of VLPs by APCs can lead to the stimulation of both the humoral and cell-mediated arms of the immune system. Historically vaccines have been designed to target the initiation of humoral immunity, generating vaccine-specific antibodies. While this type of immune response is essential for the clearance of extracellular pathogens, establishing protection against intracellular conditions such as viral infections and cancer often requires the generation of cell-mediated immunity. The ability of VLPs to stimulate both arms of the immune system is advantageous, as the combination of immune responses often work synergistically to ensure disease clearance and the initiation of effective immunological memory. The immune response to VLPs is summarised in Fig. [9.5](#Fig5){ref-type="fig"}.Fig. 9.5Antigen presenting cell (APC) cross-presentation pathways. APCs can cross-present exogenous antigens onto MHC-I through pathways including: (**a**) Gap junctions; (**b**) Endosome-to-cytosol; (**c**) ER-Endosome fusion; (**d**) Receptor recycling; and (**e**) Exosomes. Peptides derived from RHDV VLPs are known to be crosspresented through the receptor recycling pathway (Win et al. [@CR93]). Adapted from Groothuis and Neefjes ([@CR30])

Following internalisation VLPs are degraded and processed through the exogenous antigen processing pathway with immunogenic peptides loaded onto MHC class II (MHC-II) molecules for surface presentation. Processed antigens are recognised by CD4^+^ T helper cells, resulting in activation and release of immunostimulatory cytokines, such as Interleukin (IL) 4, IL-5, which are essential for B cell activation or IL-2 and IFNγ, which are essential for induction of cell-mediated immunity. For successful activation of the humoral immune system, B cells must also interact with native antigen through B cell receptors (BCRs). The repetitive nature of VLPs promotes crosslinking of BCRs, enhancing activation and promoting memory-cell formation. This stimulation is notably superior to soluble peptides or non-repetitive proteins (Jegerlehner et al. [@CR33]; Bachmann and Jennings [@CR2]). Antibodies produced in response to VLPs can neutralise native virions to prevent active infection, and memory-cell formation promotes long-term immunity. Notable examples of licensed VLP vaccines that successfully induce high titres of long-lasting neutralising antibodies include the Hepatitis B vaccine Engerix (Keating and Noble [@CR37]) and the HPV vaccines Cervarix and Gardasil (Romanowski [@CR74]).

Some VLPs are also cross-presented by APCs, primarily CD8^+^ dendritic cells, facilitating loading of exogenous antigen onto MHC class I (MHC-I). With additional stimulation from co-stimulatory molecules (e.g. CD40, CD80/86), MHC-I loaded with immunogenic peptides can activate CD8^+^ T cells to initiate a cell-mediated immune response. Cytotoxic T lymphocyte (CTL) activation is advantageous for clearance of intracellular conditions such as viral infection or cancer. For example, RHDV VLPs are processed through the receptor-recycling pathway for cross-presentation. Immunogenic peptides are loaded onto MHC-I when phagolysosomes containing degraded VLPs fuse with endosomes containing MHC-I molecules recycling from the cell surface (Win et al. [@CR93]). The endosomes return to the cell surface, displaying new MHC--peptide complexes on the cell membrane as illustrated in Fig. [9.6](#Fig6){ref-type="fig"}.Fig. 9.6The immune response to VLPs. VLPs have the capacity to stimulate both the cell-mediated and humoral immune system. The desired immune response can be promoted through adjuvant selection

The site of vaccine administration can play an important role in VLP immunogenicity. As the mucosal membranes (e.g. respiratory tract, digestive tract, urogenital tract) are a common route of infection, generation of mucosal immunity can provide early protection against pathogenic intrusion. A number of preclinical VLP vaccine trials have demonstrated that VLPs have the ability to initiate potent mucosal immunity. For example, intranasal vaccination with cholera toxin B conjugated to simian immunodeficiency virus VLPs significantly increased the levels of antibody detected in the mucosae compared to unconjugated cholera toxin B (Kang et al. [@CR35]).

Depending on the protein expression system used, some VLPs can contain exogenous immunogenic molecules such as bacterial RNA which promote APC activation through stimulation of pattern recognition receptors such as toll-like receptors (TLRs) (Rebeaud and Bachmann [@CR72]). This can have an adjuvanting effect due to activation of the innate immune system; however, we have found that successful vaccination can be achieved in the absence of these adjuvanting molecules (Li et al. [@CR47]). RHDV VLPs produced in insect cell cultures do not stimulate innate cells cultured in vitro, but effectively activate the cell-mediated and humoral immune systems in vivo. Despite the success of VLP vaccination alone, the inclusion of an adjuvant can still be beneficial in driving specific immune pathway activation and leading to further enhancement of immune stimulation.

A number of adjuvants have been used in humans; these include mineral salts (e.g. aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphates), emulsions (e.g. MF59, AS01, and AS02), and microbial derivatives (mono-phosphoryl lipid A and CpG) (Rappuoli et al. [@CR71]). Traditionally adjuvants were used to enhance vaccine immunogenicity by stimulating the humoral immune system to induce antibody production and isotype-switching. This was thought to be facilitated by formation of a slow-release antigen depot. Modern adjuvants are designed to directly target immune activation and to tailor vaccination to drive a specific immune response, enabling selective stimulation of the cell-mediated immune system. TLR agonists such as unmethylated CpG DNA can induce a potent cell-mediated response by stimulating upregulated expression of co-stimulatory molecules in innate immune cells. We have found that the addition of CpG to recombinant RHDV VLP containing the SIINFEKL peptide derived from the model antigen OVA (VLP.OTI) led to an enhancement in the generation of SIINFEKL-specific cytotoxic T cells (Fig. [9.7](#Fig7){ref-type="fig"}) (Scullion [@CR80]). This association was also confirmed using the Lewis' lung carcinoma model with recombinant gp33 RHDV VLP (Li et al. [@CR47]).Fig. 9.7The effect of CpG adjuvant on in vivo cytotoxicity. Co-administration of RHDV VLP containing the SIINFEKL peptide (VLP.OTI) with CpG significantly increased % specific lysis of target cells loaded with SIINFEKL peptide (Scullion [@CR80])

Co-delivery of vaccine adjuvants and antigens to cells through physical association or linkage leads to enhanced immunogenicity and a reduction in adjuvant-related side effects. Viruses often bind molecules that facilitate entry into host cells. RHDV VLPs retain the ability of its native virus to bind carbohydrate moieties, providing a useful mechanism for modification and vaccine enhancement (Ruvoen-Clouet et al. [@CR75]; McKee et al. [@CR58]). α-Galactosylceramide is a glycolipid adjuvant which was found to directly associate with RHDV VLP, forming a composite particle. α-Galactosylceramide activates natural killer-like T cells, leading to the enhancement of both the innate and acquired immune responses (Bendelac et al. [@CR5]). Prophylactic vaccination with recombinant gp33. RHDV VLP and α-galactosylceramide led to the generation of gp33-specific T cells and enhanced protection against subcutaneous tumour challenge. The adjuvanting effect of α-galactosylceramide was increased \>10-fold when delivered as a composite particle compared to the co-delivery of unassociated α-galactosylceramide and recombinant gp33.RHDV VLP (McKee et al. [@CR58]).

Conclusion {#Sec7}
==========

The primary requirements of a successful vaccine include safety, reliability, and efficacy. Along with other subunit vaccines VLPs have an impeccable safety record, with some vaccines already approved for routine use. The absence of the viral genome renders VLPs incapable of infection or replication, preventing inadvertent reversion as has occurred with attenuated viruses. Extensive purification of VLPs produced using protein expression systems helps to limit contamination with substances which might induce allergies or undesirable side effects. Each new VLP is extensively characterised during development, containing immunogenic epitopes in a more natural state than inactivated virus vaccines. The particulate nature of VLPs also provides some protection from degradation. VLPs are uniform in structure, providing consistency between preparations and a reliable vaccine. VLPs are readily processed by the immune system and can stimulate cytotoxic and humoral immune responses. VLPs can provide protection against their source virus, or they can harbour exogenous antigens. This unprecedented versatility in vaccine design enables the utilisation of VLP vaccines in a wide range of applications including prophylactic viral vaccines, therapeutic cancer vaccines, and even gene delivery. VLP vaccines have only begun to unveil their true potential as a versatile subunit vaccine platform.
